SPOTLIGHT: Bioheart stumbles out of the IPO gate

Going public wasn't easy for Bioheart. After delaying its IPO twice and slashing its prospective share price from a range of $14 to $16 to $6 to $8, the Sunrise, FL-based biotech saw its share price quickly slip from its $5.25 a share offering on its first day of trading on Tuesday. The biotech raised about $5.8 million in a tough market. Much of that money will go to funding clinical trials of its cell therapy for heart damage. Release | Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."